What actually happens, week by week
The clinical trial charts show smooth curves of weight loss over 68–72 weeks. Reality is messier — there are plateaus, side-effect flares during dose increases, and weeks where the scale doesn't move. This guide describes the typical pattern most patients experience, based on clinical data and real-world reports, so you know what to expect and when to worry (or not).
Month 1: Starting dose — the adjustment period
Dose: Semaglutide 0.25mg or tirzepatide 2.5mg weekly.
What you'll feel: Mild appetite reduction — you may notice you're simply less interested in food, or that smaller portions feel satisfying. Some patients describe the reduction of "food noise" — the constant background chatter about what to eat next. GI side effects (mild nausea, possible constipation) are most common during the first 1–2 weeks and usually subside.
Weight: Minimal — typically 1–3 pounds. This is a titration dose, not a therapeutic dose. Don't be discouraged.
Priority: Establish your protein intake (70–100g daily), hydration (64+ oz water), and injection routine. These habits matter more than the scale in month one.
Month 2: First dose increase
Dose: Semaglutide 0.5mg or tirzepatide 5mg.
What you'll feel: More noticeable appetite suppression. Nausea may briefly return for 3–7 days after the dose increase, then subside. Some patients notice their relationship with food changing — eating out of habit rather than hunger becomes more obvious.
Weight: Most patients start seeing measurable movement — 3–5% of starting body weight by end of month 2. For a 200-pound person, that's 6–10 pounds.
Month 3: Building momentum
Dose: Semaglutide 1.0mg or tirzepatide 7.5mg.
What you'll feel: Appetite suppression is now consistent. Most patients are eating 30–50% less than pre-treatment without effort. Side effects from previous dose increases have typically resolved. Some patients notice changes in food preferences — sweets or high-fat foods become less appealing.
Weight: 5–8% from baseline is typical. Clothing starts fitting differently. This is where many patients first feel confident the medication is working.
Month 4: Approaching maintenance dose
Dose: Semaglutide 1.7mg or tirzepatide 10mg.
What you'll feel: This is often the last dose increase that causes noticeable GI adjustment. If you've tolerated doses well so far, this increase is usually manageable. Energy levels often improve as weight decreases and metabolic markers improve.
Weight: 8–12% from baseline. Lab work improvements often show up at this point — lower fasting glucose, improved lipids, reduced blood pressure.
Month 5–6: Maintenance territory
Dose: Semaglutide 2.4mg or tirzepatide 12.5–15mg (or the dose where your provider determines the optimal balance of efficacy and tolerability).
What you'll feel: Side effects have generally resolved. Appetite regulation feels natural rather than medication-imposed. Weight loss continues but at a slower rate — this is normal. The steepest weight loss occurs in months 2–5; months 6+ show continued but decelerating progress.
Weight: 10–15% from baseline for semaglutide, 13–20% for tirzepatide. Not every patient reaches these averages — some exceed them, some fall short. Individual biology matters.
When to contact your provider
Most side effects are manageable, but contact your provider if nausea or vomiting is severe enough to prevent eating or drinking for more than 24 hours, you experience severe abdominal pain (possible pancreatitis or gallbladder), you notice a lump or swelling in your neck (thyroid concern), you develop signs of allergic reaction (rash, swelling, difficulty breathing), or your mood changes significantly during treatment.